Personal information

Verified email addresses

molecular & biochemical pharmacology, immunopharmacology, global medical & scientific communications, global medical affairs, strategic publication planning, Medical writing, strategic consulting medical communications & medical affairs, Rx, OTC, & consumer product discovery & development, anti-inflammatory agents, anticancer drug discovery, post-surgical local anesthetics, Coxibs and NSAIDs, pain mechanisms and clinical measures, analgesics, topical NSAID products, epinephrine auto-injectors for treatment of anaphylaxis, dental products research & development, periodontal disease research & development, anti-rheumatic drugs and biologics, HPV vaccines, nucleic acids, antisense oligonucleotides, chemical & enzymatic synthesis of modified polynucleotides, translational clinical research, biotechnology, clinical measures validation, biomarkers, skincare cosmetics, general pharmacology, green chemistry

Activities

Employment (14)

Fairleigh Dickinson University: Madison, NJ, US

2018 to present | Adjunct Professor (School of Pharmacy and Health Sciences)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Estée Lauder Comapanies: Melville, NY, US

2020-03 to 2024-07-15 | Executive Fellow Global Product Stewardship (Global Product Safety, Regulatory Affairs & Green Chemistry)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Pacira BioSciences Inc: Parsippany, NJ, US

2017-01 to 2020-03 | Director Scientific Communications (Medical Sciences)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Vertex Pharmaceuticals Inc: Boston, MA, US

2017 to 2017 | Senior Director Medical Publications (Global Medical Affairs)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Sanofi-Aventis US LLC: Bridgewater, NJ, US

2014 to 2017 | Director Global Publications Sarilumab and Dupilumab (Global Medical Affairs)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Mylan NV: Canonsburg, PA, US

2012 to 2014-10 | Senior Manager Scientific Communications (Medical Affairs)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Shionogi Inc: Florham Park, NJ, US

2010 to 2012 | Director of Publication Planning
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Alpharma/King Pharmaceuticals: Piscataway, NJ, US

2008 to 2010 | Associate Director Scientific Communications (Medical Affairs)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Bayer HealthCare Pharmaceuticals Inc: Whippany, NJ, US

2007 to 2008 | Deputy Director Global Publications Oncology - Nexavar (U.S. Medical and Scientific Affairs)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Merck Research Rahway: Rahway, NJ, US

2003 to 2007 | Associate Director Medical Communications (Clinical Immunology and Analgesia, Clinical and Quantitative Sciences Division )
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Procter and Gamble Co: Cincinnati, OH, US

1992 to 2003 | Senior Research Scientist (Oral Care Product Development/New Drug Development)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

University of Cincinnati College of Medicine: Cincinnati, OH, US

1993 to 1999 | Volunteer Associate Professor (Otolaryngology)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Sterling Winthrop: Malvern, PA, US

1985 to 1992 | Senior Scientist Drug Discovery (Virology and Oncopharmacology)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Roswell Park Cancer Institute: Buffalo, NY, US

1982 to 1985 | Cancer Research Scientist (Experimental Therapeutics)
Employment
Source: Self-asserted source
Paul F. Cavanaugh

Education and qualifications (2)

University at Buffalo School of Pharmacy and Pharmaceutical Sciences: Buffalo, NY, US

1977 to 1983 | PhD (Biochemical Pharmacology)
Education
Source: Self-asserted source
Paul F. Cavanaugh

Boston College: Chestnut Hill, MA, US

1973 to 1977 | BS (Chemistry)
Education
Source: Self-asserted source
Paul F. Cavanaugh

Professional activities (1)

Procter and Gamble Co: Cincinnati, OH, US

1994 | Procter and Gamble Health Care Product Development STARRS Award for Excellence in Technology. This award is awarded annually to an individual in Health Care Product Development as the leading research scientist for that year. Recipients are nominated by their scientific peers. (Healthcare Product Development)
Distinction
Source: Self-asserted source
Paul F. Cavanaugh

Funding (1)

The Chemotherapeutic Potential of Polyamine Derivatives

1984 to 1984 | Award
American Cancer Society (GA, GA, US)
GRANT_NUMBER:

PF-2425

Source: Self-asserted source
Paul F. Cavanaugh

Works (50 of 57)

Items per page:
Page 1 of 2

Persistent opioid use after cesarean delivery in the United States of America: a systematic review.

International journal of obstetric anesthesia
2023-02-27 | Journal article
Contributors: Ruthi Landau; Cavanaugh PF; DiGiorgi M
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Applying Green Chemistry to Raw Material Selection and Product Formulation at The Estée Lauder Companies

Green Chemistry
2021-12-08 | Journal article
Part of ISSN: 1463-9262
Part of ISSN: 1463-9270
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 3)‎

Allergic/infusion reactions reported with cetuximab and rituximab

3rd WAO International Scientific Conference, WISC 2014
2015-04-08 | Conference paper
Source: Self-asserted source
Paul F. Cavanaugh

Comparison of needle penetration depth probabilities of two epinephrine auto-injectors

Australasian Society of Clinical Immunology and Allergy (ASCIA) 25th Annual Conference
2014-09 | Conference paper
Part of ISSN: 1444-0903
Source: Self-asserted source
Paul F. Cavanaugh

Factors Associated With a Lower Probability Of Refilling An Epipen Auto-Injector In a Timely Manner

2014 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, AAAAI 2014
2014-02-28 | Conference paper
Part of ISSN: 0091-6749
Source: Self-asserted source
Paul F. Cavanaugh

Methodology for identifying patients presenting with anaphylaxis using administrative claims data

2014 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, AAAAI 2014
2014-02-28 | Conference paper
Source: Self-asserted source
Paul F. Cavanaugh

Design of the EpiPen Auto-Injector.

The Journal of allergy and clinical immunology
2013-05-29 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions.

Therapeutics and clinical risk management
2012-01-25 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions.

Therapeutics and clinical risk management
2012-01-25 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Pharmacokinetic profile of clonidine hydrochloride extended-release tablets in children and adolescents with attention-deficit hyperactivity disorder

The 51st Annual National Institute of Mental Health (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, Florida, June 13–16, 2011Posters Most Relevant to Child and Adolescent Psychopharmacology
2011-12-13 | Conference paper
Part of ISSN: 1044-5463
Part of ISSN: 1557-8992
Source: Self-asserted source
Paul F. Cavanaugh

Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis.

Journal of clinical pharmacology
2009-10-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.

Journal of clinical pharmacology
2008-04-23 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib.

Journal of clinical pharmacology
2007-07-26 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: A 12-week randomized controlled clinical trial with a 52-week open-label extension

Journal of Rheumatology
2006 | Journal article
EID:

2-s2.0-33646450531

Part of ISSN: 0315162X
Contributors: Reiff, A.; Lovell, D.J.; Van Adelsberg, J.; Kiss, M.H.B.; Goodman, S.; Zavaler, M.F.; Chen, P.-Y.; Bolognese, J.A.; Cavanaugh Jr., P.F.; Reicin, A.S. et al.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.

Current medical research and opinion
2006-12-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Pediatrics
2006-11-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Evaluation of the effect of perioperative rofecoxib treatment on pain control and clinical outcomes in patients recovering from gynecologic abdominal surgery: a randomized, double-blind, placebo-controlled clinical study.

Regional anesthesia and pain medicine
2006-03-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.

Mayo Clinic proceedings
2005-05-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.

Annals of the rheumatic diseases
2005-02-24 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Etoricoxib

Drugs of Today
2004 | Journal article
EID:

2-s2.0-3042780168

Part of ISSN: 16993993 16994019
Contributors: Matsumoto, A.K.; Cavanaugh Jr., P.F.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.

Clinical Cancer Research : an official journal of the American Association for Cancer Research
2004-03-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Relationship between age, renal function and bone mineral density in the US population.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
2003-07-03 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

The overexpression of cyclo-oxygenase-2 in chronic periodontitis.

Journal of the American Dental Association (1939)
2003-07-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2000-08-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh

Coordinate production of PGE<sub>2</sub> and IL-1β in the gingival crevicular fluid of adults with periodontitis: Its relationship to alveolar bone loss and disruption by twice daily treatment with ketorolac tromethamine oral rinse

Journal of Periodontal Research
1998 | Journal article
EID:

2-s2.0-0031995419

Part of ISSN: 00223484
Contributors: Cavanaugh Jr., P.F.; Meredith, M.P.; Buchanan, W.; Doyle, M.J.; Reddy, M.S.; Jeffcoat, M.K.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

The Use of Ketorolac Tromethamine Oral Rinse for the Treatment of Periodontitis in Adults

In: Rainsford K.D. (eds) Side Effects of Anti-Inflammatory Drugs IV. Springer, Dordrecht
1997 | Book chapter
Source: Self-asserted source
Paul F. Cavanaugh

Development of a MIMIC-based polymerase chain reaction technique for the analysis of prostaglandin endoperoxide H synthase isoenzyme cDNAs.

Analytical biochemistry
1997-08-01 | Journal article
PMID: 9300090
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Prostaglandin H synthase isoenzyme distribution in the gingival tissue of patients with periodontitis: pronounced expression adjacent to gram-positive bacteria.

Inflammopharmacology
1997-01-01 | Journal article
Source: Self-asserted source
Paul F. Cavanaugh

The activation of murine macrophages and natural killer cells by the partially thiolated double stranded RNA poly(I)·mercapto poly(C)

Research Communications in Molecular Pathology and Pharmacology
1996 | Journal article
EID:

2-s2.0-0029983043

Part of ISSN: 00345164
Contributors: Cavanaugh Jr., P.F.; Ho, Y.-K.; Bardos, T.J.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Validation of quantitative digital subtraction radiography using the electronically guided alignment device/impression technique.

Journal of periodontology
1996-09-01 | Journal article
PMID: 8884647
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Efficacy of quantitative digital subtraction radiography using radiographs exposed in a multicenter trial.

Journal of periodontal research
1996-04-01 | Journal article
PMID: 8814584
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

The activation of murine macrophages and natural killer cells by the partially thiolated double stranded RNA poly(I)-mercapto poly(C).

Research communications in molecular pathology and pharmacology
1996-02-01 | Journal article
PMID: 8832906
Source: Self-asserted source
Paul F. Cavanaugh

Immunohistochemical localization of prostaglandin H synthase isoenzyme proteins in the gingival tissue of patients with periodontitis

Inflammopharmacology
1995 | Journal article
EID:

2-s2.0-0029008958

Part of ISSN: 09254692 15685608
Contributors: Cavanaugh, P.F.; Mcdonald, J.S.; Pavelic, L.; Limardi, R.J.; Gluckman, J.L.; Pavelic, Z.P.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

The use of ketorolac tromethamine oral rinse for the treatment of periodontitis in adults

Inflammopharmacology
1995 | Journal article
EID:

2-s2.0-0029568025

Part of ISSN: 09254692 15685608
Contributors: Cavanaugh, P.F.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx

1995-03-13 | Patent
PAT:

US5626838A

Source: Self-asserted source
Paul F. Cavanaugh

Diisopropylsilyl-linked oligonucleotide analogs: solid-phase synthesis and physicochemical properties

The Journal of Organic Chemistry
1993-12 | Journal article
Part of ISSN: 0022-3263
Part of ISSN: 1520-6904
Source: Self-asserted source
Paul F. Cavanaugh
grade
Preferred source (of 2)‎

Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay

Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development
1992 | Book chapter
Part of ISBN: 9781461365488
Part of ISBN: 9781461534921
Source: Self-asserted source
Paul F. Cavanaugh

Large Scale Anticancer Drug Screening at Sterling Drug Inc.

Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development
1992 | Book chapter
Part of ISBN: 9781461365488
Part of ISBN: 9781461534921
Source: Self-asserted source
Paul F. Cavanaugh

A semi-automated neutral red based chemosensitivity assay for drug screening

Investigational New Drugs
1990 | Journal article
EID:

2-s2.0-0025085950

Part of ISSN: 01676997 15730646
Contributors: Cavanaugh Jr., P.F.; Moskwa, P.S.; Donish, W.H.; Pera, P.J.; Richardson, D.; Andrese, A.P.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Exonuclease resistant terminally substituted oligonucleotides

1990-08-03 | Patent
PAT:

US5245022A

Source: Self-asserted source
Paul F. Cavanaugh

Nuclease resistant compounds

1990-08-03 | Patent
PAT:

US5567810A

Source: Self-asserted source
Paul F. Cavanaugh

Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleotide analogues

1990-08-03 | Patent
PAT:

US5677439A

Source: Self-asserted source
Paul F. Cavanaugh

Antisense DNA (ASD) mediated inhibition of protein synthesis. Dependence on target mRNA primary and secondary structure.

Proc. Am. Assoc. Cancer Res. 1989
1989 | Conference abstract
Contributors: Paul F. Cavanaugh; William Pilgermayer
Source: Self-asserted source
Paul F. Cavanaugh

Structural determinants of spermidine-DNA interactions.

Biopolymers
1987-05-01 | Journal article
PMID: 3593890
Source: Self-asserted source
Paul F. Cavanaugh

Biochemical and cell cycle effects of the bacterial siderophores, parabactin (PB) and N<sup>1</sup>,N<sup>8</sup>-dihydroxybenzoylspermidine (CPD-II) in L1210 leukemia cells

Proceedings of the American Association for Cancer Research
1985 | Journal article
EID:

2-s2.0-17344381234

Contributors: Cavanaugh Jr., P.F.; McManis, J.S.; Frankfurt, O.S.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Biological Properties of N<sup>4</sup>- and N<sup>1</sup>,N<sup>8</sup>-Spermidine Derivatives in Cultured L1210 Leukemia Cells

Cancer Research
1985 | Journal article
EID:

2-s2.0-0021893570

Part of ISSN: 15387445 00085472
Contributors: Porter, C.W.; Cavanaugh, P.F.; Ganis, B.; Kelly, E.; Bergeron, R.J.; Stolowich, N.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Characterization of L1210 Cell Growth Inhibition by the Bacterial Iron Chelators Parabactin and Compound II

Cancer Research
1985 | Journal article
EID:

2-s2.0-0022357907

Part of ISSN: 15387445 00085472
Contributors: Cavanaugh, P.F.; Porter, C.W.; Frankfurt, O.S.; Pavelic, Z.P.; Bergeron, R.J.; Tukalo, D.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Enzyme regulation by polyamine analogs: An alternative approach to inhibition of polyamine biosynthesis

Proceedings of the American Association for Cancer Research
1985 | Journal article
EID:

2-s2.0-17344378605

Contributors: Porter, C.W.; Cavanaugh Jr., P.F.; Bergeron, R.J.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Inhibition of L1210 cell growth by N<sup>1</sup>,N<sup>8</sup>-bis(ethyl)-spermidine (BES), a regulator of polyamine biosynthesis

Proceedings of the American Association for Cancer Research
1985 | Journal article
EID:

2-s2.0-17144465981

Contributors: Cavanaugh Jr., P.F.; Bergeron, R.J.; Porter, C.W.
Source: Self-asserted source
Paul F. Cavanaugh via Scopus - Elsevier

Characterization of L1210 cell growth inhibition by the bacterial iron chelators parabactin and compound II.

Cancer research
1985-10-01 | Journal article
PMID: 4027962
Source: Self-asserted source
Paul F. Cavanaugh
Items per page:
Page 1 of 2